Form 4: Royalty Pharma EVP Christopher Hite Acquires Class E Ordinary Shares

Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, reports the acquisition of Class E ordinary shares through an indirect transaction.

Summary

• Christopher Hite, EVP & Vice Chairman of Royalty Pharma plc, filed a Form 4 indicating changes in beneficial ownership.
• The report details the indirect acquisition of 1,238,789 Class E ordinary shares of Royalty Pharma Holdings Ltd (RPH) pursuant to Rule 16b-3.
• This acquisition is connected to the Membership Interests Purchase Agreement dated January 10, 2025.
• The Class E shares vest in installments over a 9-year period and can be converted into Class B ordinary shares of RPH on a one-for-one basis.
• Class B shares can then be converted into Class A ordinary shares of Royalty Pharma plc on a one-for-one basis.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices and aligns management interests with the company's long-term performance. There are no explicit negative implications.

Future Outlook

The Class E shares will vest over a 9-year period, implying a long-term incentive structure for the reporting person.

Industry Context

This filing reflects standard executive compensation practices within publicly traded companies, particularly those involving equity-based awards to align management interests with shareholder value.

Stakeholder Impact

• The acquisition of shares by a top executive can be viewed positively by shareholders as it aligns management's interests with the company's performance.

Key Dates

Keywords

Royalty Pharma, Christopher Hite, Class E Ordinary Shares, Beneficial Ownership, Form 4, RPRX, RPH, Membership Interests Purchase Agreement